Join the race to end the pandemic
Together we can make history, restart economies and save lives
UNICEF is looking for partners who can make history with us. Partners that can contribute to making big things happen.
In the race to end the pandemic, UNICEF is leading efforts to deliver COVID-19 vaccines, tests and treatments, as well as protective equipment, for more than 100 countries, on behalf of ACT-A and the COVAX Facility. This is the world’s largest and fastest ever procurement and delivery of vaccines and one of the largest humanitarian operations to date.
We have already delivered 1 billion vaccine doses, but to end this race UNICEF urgently needs more partners that can help deliver history and ensure the vaccines, tests and treatments are accessible for every country that needs them.
“Under the most extreme scenario, in which rich countries receive vaccines this year but emerging and developing countries do not, the hit to global output would be US$9.2 trillion.”
The Financial Times based on a study by the International Chamber of Commerce
Can’t see or use this form? Email corporate-partnerships@unicef.org directly and we’ll be in touch shortly.
This contact form is intended for individuals or institutions interested in making substantial financial contributions to help UNICEF rapidly deliver COVID-19 vaccines in low-and middle-income countries. A member of the team will be in touch with you personally in the coming days to discuss potential partnership options. Thank you for your interest. View our privacy policy.
Why partner with UNICEF?
Funded entirely by voluntary donations, UNICEF is the largest single buyer and distributor of vaccines in the world, helping to protect nearly half the world’s children from preventable diseases in any given year. In 2019, 2.43 billion doses of vaccines were delivered to children in nearly 100 countries.
UNICEF and partners are scaling up the cold chain and equipping healthcare workers to administer hundreds of millions of COVID-19 vaccines, treatments and tests to more than 100 low- and middle-income countries.
Funding will help these countries immunize at-risk populations and frontline workers, protect healthcare staff, and provide treatments and diagnostic equipment to millions of people, preventing severe illness and deaths, as well as the appearance of new dangerous variants.
